摘要
目的观察紫杉醇联合卡培他滨治疗晚期进展期胃癌的临床疗效和不良反应。方法 20例晚期胃癌患者,均采用紫杉醇联合卡培他滨化疗方案。卡培他滨1 000 mg/m2,早、晚饭后30分钟内口服,第1-14天,间歇7天;紫杉醇135 mg/m2,分2次静脉滴注(第1、8天)。21天为1疗程。结果 20例患者治疗后,部分缓解5例(25.0%),稳定12例(60.0%),进展3例(15.0%),治疗有效率为25.0%,疾病控制率为85.0%;中位缓解期5月,中位生存期12月。不良反应主要为骨髓抑制和手足综合征,且多为Ⅰ～Ⅱ度,大部分患者可耐受。结论 紫杉醇联合卡培他滨治疗晚期胃癌有一定疗效,对多程化疗失败的晚期胃癌患者可通过该化疗方案获益,值得临床进一步研究应用。
Objective To investigate the clinical effect and side effects of paclitaxel combined with eapecitabine in the treatment for patients with advanced gastric cancer. Methods Twenty patients with advanced gastric cancer recurrence after chemotherapy were treated with the combination of paclitaxel and capecitabine. The patients were administrated with oral eapecitabine （ 1 000 mg/m^2, bid, d 1 - 14） and intravenous paclitaxel （ 135 mg/m^2, d 1, d 8） in a 21-day cycle regimen. Results A total of 5 cases showed PR （25. 0% ） , 12 SD （60.0%） and 3 PD （ 15.0% ）. Meanwhile,the response rate （RR） was 25.0% and the disease control rate （DCR） was 85.0%. The median remission time and the median survival time were 5 months and 12 months, respectively. Tile main side effects were myelosuppression and hand-foot syndrome. The degree of these side reactions were only Ⅰ or Ⅱ level. Conclusion The combination of paclitaxel and capecitabine is effective and well-tolerated in the treatment of advanced gastric cancer recurrence after chemotherapy.
出处
《实用肿瘤杂志》
CAS
2013年第1期68-70,共3页
Journal of Practical Oncology
关键词
胃肿瘤
药物疗法
紫杉醇
治疗应用
卡培他滨
治疗应用
生活质量
stomach neoplasms/drug therapy
paclitaxeL/therapeutic use
capecitabine/therapeutic use
quality of life
